ACUTE MYELOID LEUKEMIA RECURRENT
Clinical trials for ACUTE MYELOID LEUKEMIA RECURRENT explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA RECURRENT trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to beat back stubborn leukemia
Disease control Recruiting nowThis study tests a combination of four drugs, called CLAG-GO, in adults whose acute myeloid leukemia (AML) has not responded to standard treatment or has come back after remission. Participants receive the drugs during a hospital stay, and if the cancer goes into remission, they …
Matched conditions: ACUTE MYELOID LEUKEMIA RECURRENT
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jul 02, 2026 05:00 UTC
-
New immune cell combo aims to stop leukemia relapse
Disease control Recruiting nowThis early-phase study tests whether giving specially trained immune cells (CIML NK cells) along with a targeted drug (venetoclax) can safely help prevent acute myeloid leukemia (AML) from coming back. Ten adults with AML who have already received standard treatment will receive …
Matched conditions: ACUTE MYELOID LEUKEMIA RECURRENT
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug cocktail aims to tackle tough leukemia
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called ziftomenib alongside standard treatments for acute myeloid leukemia (AML) in people with specific gene mutations. About 420 participants with newly diagnosed or relapsed AML will be assigned to one of three treatment a…
Matched conditions: ACUTE MYELOID LEUKEMIA RECURRENT
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC